Association between vaccine dose and risk of hepatitis B virus infection in Fujian Province, China

References

• Wang H, Men P, Xiao Y, Gao P, Lv M, Yuan Q, Chen W, Bai S, Wu J. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect Dis. 2019;19:811. doi:10.1186/s12879-019-4428-y.
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Nicholas S, Maitland E, Fei T. Regional differences of hepatitis B discrimination in rural China. Hum Vaccin Immunother. 2021;17(7):2257–7. doi:10.1080/21645515.2020.1853999.
   PubMed Web of Science ®Google Scholar
• Xia GL, Liu GB, Cao HL, Bi S, Zhan M, Su C, Nan J, Qi X. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun. 1996;5:62–73. doi:10.1016/S0928-4346(96)82012-3.
   Web of Science ®Google Scholar
• Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Hum Vaccin Immunother. 2020;16(7):1533–44. doi:10.1080/21645515.2020.1732166.
   PubMed Web of Science ®Google Scholar
• Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J. 2009;122:3–4. doi:10.1111/j.1365-2893.2010.01266.x.
   PubMed Web of Science ®Google Scholar
• Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97(3):230–38. doi:10.2471/BLT.18.219469.
   PubMed Web of Science ®Google Scholar
• Liang XF, Bi SL, Yang WZ, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–57. doi:10.1016/j.vaccine.2009.08.048.
   PubMed Web of Science ®Google Scholar
• Wu JN, Wen XZ, Zhou Y, Lin D, Zhang SY, Yan YS. Impact of the free-vaccine policy on timely initiation and completion of hepatitis B vaccination in Fujian, China. J Viral Hepat. 2015;22(6):551–60. doi:10.1111/jvh.12359.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhou Y, Yang X. Epidemiological characteristics of hepatitis B infection in 1–29 year old population in Fujian Province. Strait J Pre Med. 2018;24:32–33.
   Google Scholar
• Wu JN, Zhou Y, Zhang DJ, Zheng JF, Pan WY, Cai ZK, Yan YS. Study on the authenticity of immunization coverage of the routine immunization coverage surveillance system of Fujian. Chin J Epidemiol. 2011;32(9):946–48.
   Google Scholar
• Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010;51(2):405–14. doi:10.1002/hep.23310.
   PubMed Web of Science ®Google Scholar
• Tang J, Luo YQ, Zhou YH. Elimination of hepatitis B virus infection in children: experience and challenge in China. Chinese Med J. 2021;134(23):2818–24. doi:10.1097/CM9.0000000000001791.
   PubMed Web of Science ®Google Scholar
• Wu JN, Li DJ, Zhou Y. Association between timely initiation of hepatitis B vaccine and completion of the hepatitis B vaccine and national immunization program vaccine series. Int J Infect Dis. 2016;51:62–65. doi:10.1016/j.ijid.2016.08.018.
   PubMed Web of Science ®Google Scholar
• Cui F, Shen L, Li L, Wang H, Wang F, Bi S, Liu J, Zhang G, Wang F, Zheng H, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis. 2017;23(5):765–72. doi:10.3201/eid2305.161477.
   PubMed Web of Science ®Google Scholar
• Fujian Provincial Health Commission, Fujian Center for Disease Control and Prevention. 40th Anniversary of Immunization Program in Fujian province. Fujian Science and Technology Press; 2019 Sept.
   Google Scholar
• Liao X, Liang Z. Strategy vaccination against hepatitis B in China. Hum Vaccin Immunother. 2015;11(6):1534–39. doi:10.4161/21645515.2014.980206.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu H, Wang Y, Hao R, Li Z, Song H. The next step in controlling HBV in China. BMJ. 2013 Jul 16;347(1):f4503. doi:10.1136/bmj.f4503.
   PubMedGoogle Scholar
• Moyes CD, Milne A, Dimitrakakis M, Goldwater PN, Pearce N. Very-low-dose hepatitis B vaccine in newborn infants: an economic option for control in endemic areas. Lancet. 1987;1(8523):29–31. doi:10.1016/S0140-6736(87)90712-4.
   PubMed Web of Science ®Google Scholar
• Kane M. Reduced doses of hepatitis B vaccines: is it a good idea? Bull World Health Organ. 1995;73:529–30.
   PubMed Web of Science ®Google Scholar
• Pileggi C, Papadopoli R, Bianco A, Pavia M. Hepatitis B vaccine and the need for a booster dose after primary vaccination. Vaccine. 2017;35:6302–07. doi:10.1016/j.vaccine.2017.09.076.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore A, Bell B, Hennessy T. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200:1390–96. doi:10.1086/606119.
   PubMed Web of Science ®Google Scholar
• ul-Haq N, Hasnain SS, Umar M, Abbas Z, Valenzuela-Silva C, Lopez-Saura P. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. Vaccine. 2003;21(23):3179–85. doi:10.1016/S0264-410X(03)00232-9.
   PubMed Web of Science ®Google Scholar
• Chiaramonte M, Majori S, Ngatchu T, Moschen ME, Baldo V, Renzulli G, Simoncello I, Rocco S, Bertin T, Naccarato R, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine. 1996;14(2):135–37. doi:10.1016/0264-410X(95)00148-T.
   PubMed Web of Science ®Google Scholar
• Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health. 1995;16(1):12–17. doi:10.1016/1054-139X(94)00105-N.
   PubMed Web of Science ®Google Scholar
• Feng Y, Yao T, Han Y, Shi J, Dong S, Wu Y, Shao Z, Liu H, Guo H, Chai G, et al. Immunogenicity and safety of a high-dose and prolonged-schedule hepatitis B vaccine among chronic kidney disease patients: a randomized, parallel-controlled trial. Expert Rev Vaccines. 2021;20(6):743–51. doi:10.1080/14760584.2021.1915777.
   PubMed Web of Science ®Google Scholar
• Feng Y, Shi J, Gao L, Yao T, Feng D, Luo D, Li Z, Zhang Y, Wang F, Cui F, et al. Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: a randomized, open-labeled, blank-controlled trial. Hum Vaccin Immunother. 2017;13(6):1–7. doi:10.1080/21645515.2017.1283082.
   PubMed Web of Science ®Google Scholar
• Schönberger K, Riedel C, Rückinger S, Mansmann U, Jilg W, Kries RV. Determinants of long term protection after hepatitis B vaccination in infancy: a meta-analysis. Pediatr Infect Dis J. 2013;32:307–13. doi:10.1097/INF.0b013e31827bd1b0.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zou H, Chen Y, Zhang H, Tian R, Meng J, Zhu Y, Guo H, Dai E, Zhu B, et al. The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: a prospective, multicenter, large-sample cohort study. BMC Med. 2021;19:148. doi:10.1186/s12916-021-02025-1.
   PubMed Web of Science ®Google Scholar
• Solay AH, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccin Immunother. 2019;15(5):1177–82. doi:10.1080/21645515.2019.1574151.
   PubMed Web of Science ®Google Scholar
• Shi J, Feng Y, Gao L, Feng D, Yao T, Shi S, Zhang Y, Liang X, Wang S. Immunogenicity and safety of a high-dose hepatitis B vaccine among patients receiving methadone maintenance treatment: a randomized, double-blinded, parallel-controlled trial. Vaccine. 2017;35(18):2443–48. doi:10.1016/j.vaccine.2017.03.034.
   PubMed Web of Science ®Google Scholar
• Wang J, He Y, Jin D, Liu J, Zheng J, Yuan N, Bai Y, Yan T, Yang Y, Liu Y, et al. No response to hepatitis B vaccine in infants born to HBsAg (+) mothers is associated to the transplacental transfer of HBsAg. Infect Dis (Lond). 2017;49(8):576–83. doi:10.1080/23744235.2017.1292541.
   PubMed Web of Science ®Google Scholar
• Wang B, Xu XX, Wen HX, Hao HY, Yang ZQ, Shi XH, Fu ZD, Wang XF, Zhang F, Wang SP. Influencing factors for non/low-response to hepatitis B vaccine in infants of HBsAg positive mothers. Chin J Epidemiol. 2017;38(7):911–15.
   Google Scholar
• Zhou YH, Wu C, Zhuang H. Vaccination against hepatitis B: the Chinese experience. Chin Med J. 2009;122:98–102.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lu Z, He H, Yan R, Deng X, Tang X, Zhu Y, Xu X. Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: a 5-year prospective study in Zhejiang Province, China (2016–2020). J Viral Hepat. 2021;28(10):1413–21. doi:10.1111/jvh.13581.
   PubMed Web of Science ®Google Scholar